PTC Therapeutics, Inc.

NASDAQ:PTCT

Biotechnology

Healthcare
$60.23 +0.76%

+$0.60 today

Market cap
$5.03B
Beta
0.55
P/E (TTM)
-35.0
EPS (TTM)
-$2.26
52W Low $43.18High $87.50

Volume 0.64M

Average 1.27M

PTCT Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

PTC Therapeutics, Inc.NASDAQ: PTCT

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) growth accelerates

Q2 FY2026 weighted avg shares (diluted) of 92.02M shares rose 17.7% year over year, ahead of the +7.4% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 11.5% from the prior quarter. Over 3 fiscal years it compounded at +7.2% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +17.7% holds above the trailing-twelve-month pace of +7.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
92.02M+11.5% QoQ
Last fiscal yearDec 2025
88.31M+14.9% YoY
LTMJun 2026
85.59M+7.4% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+17.7%——
1 year+14.9%——
3-year CAGR+7.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
88.31M USD
Year-over-year change
+14.9%
4-year CAGR
+5.8%

Weighted Avg Shares (Diluted) vs competitors

How PTCT compares with its peers on the latest reported figures

  • PTCT's LTM Jun 2026 weighted avg shares (diluted) of 85.59M shares is the 9th highest of the 11 companies compared; the peer median is 129.29M shares.
  • Its year-over-year change of +7.4% is the 5th highest of 11, against a peer median of +6.8%.
  • Over three fiscal years its annual growth of +7.2% compares with a peer median of +11.2%.
PTCT Competitors Peer median
Weighted Avg Shares (Diluted) for PTCT and competitors
Company Period LTM YoY 3-year CAGR
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026195.7M +0.1%+1.5%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026194.58M +2.6%+10.2%
WVEWave Life Sciences Ltd.LTM Mar 2026178.01M +19.3%+28.8%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026164.62M -0.2%+4.1%
DYNDyne Therapeutics, Inc.LTM Jun 2026150.19M +40.8%+35.2%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026108.39M +6.9%+6.2%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 202699.68M +6.6%+12.1%
SLDBSolid Biosciences Inc.LTM Mar 202698.28M +94.3%+117.4%
PTCTPTC Therapeutics, Inc.LTM Jun 202685.59M +7.4%+7.2%
CAPRCapricor Therapeutics, Inc.LTM Mar 202649.43M +35.6%+23.7%
KRYSKrystal Biotech, Inc.LTM Jun 202630.24M +1.3%+5.5%
Peer median (excluding PTCT) 129.29M+6.8%+11.2%

Competitors are the stored peer set for PTCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue538.59M698.8M937.82M806.78M1.73B
Cost of Revenue32.33M44.68M65.49M57.4M71.76M
Gross Profit506.27M654.12M872.34M749.38M1.66B
Gross Margin94.0%93.6%93.0%92.9%95.9%
Research & Development540.68M651.5M666.56M534.48M455.25M
Selling, General & Admin285.77M326M332.54M300.91M347.14M
Operating Expenses880.71M1.1B1.31B1.05B802.39M
Depreciation & Amortization64.13M128.84M236.59M75.66M38.82M
EBITDA(368.18M)(367.78M)(330.34M)(120.46M)887.66M
EBITDA Margin-68.4%-52.6%-35.2%-14.9%51.3%
Operating Income(374.44M)(447.41M)(439.5M)(302.57M)856.51M
Operating Margin-69.5%-64.0%-46.9%-37.5%49.5%
Interest Income00000
Interest Expense86.02M90.87M129.18M166.99M152.23M
Other Income / Expenses(143.9M)(140.08M)(256.61M)(60.55M)(159.89M)
Income Before Tax(518.34M)(587.49M)(696.11M)(363.12M)696.62M
Pre-Tax Margin-96.2%-84.1%-74.2%-45.0%40.3%
Income Tax Expense5.56M(28.47M)(69.51M)176K13.98M
Net Income(523.9M)(559.02M)(626.6M)(363.3M)682.64M
Net Margin-97.3%-80.0%-66.8%-45.0%39.4%
EPS (Basic)(7.43)(7.79)(8.37)(4.73)8.58
EPS (Diluted)(7.43)(7.79)(8.37)(4.73)7.78
Weighted Avg Shares70.47M71.73M74.84M76.85M79.53M
Weighted Avg Shares (Diluted)70.47M71.73M74.84M76.85M88.31M

PTC Therapeutics, Inc.

NASDAQ:PTCT

Intrinsic Alpha fair value

Locked

Current Price

$60.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.